How would you change the regimen for a patient receiving neoadjuvant TCHP or node positive HR+/HER2+ breast cancer who develops a severe allergic reaction to docetaxel?
Would you consider an anthracycline based substitution vs changing to nab-paclitaxel or a combination with platinum agent?
Answer from: Medical Oncologist at Academic Institution
I would favor replacing docetaxel with nab-paclitaxel and continue carboplatin along with trastuzumab and pertuzumab, as the data would suggest that in HER2+ breast cancer, the taxanes are more important than anthracyclines (as seen in BCIRG-006 and TRAIN-2) and that the taxanes offer synergy with H...
Sign in or Register to read more